{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:52:40Z","timestamp":1791640360717,"version":"4.3.4"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Genetic epilepsies are a spectrum of disorders characterized by spontaneous and recurrent seizures that can arise from an array of inherited or de novo genetic variants and disrupt normal brain development or neuronal connectivity and function. Genetically determined epilepsies, many of which are due to monogenic pathogenic variants, can result in early mortality and may present in isolation or be accompanied by neurodevelopmental disability. Despite the availability of more than 20 antiseizure medications, many patients with epilepsy fail to achieve seizure control with current therapies. Patients with refractory epilepsy\u2014particularly of childhood onset\u2014experience increased risk for severe disability and premature death. Further, available medications inadequately address the comorbid developmental disability. The advent of next-generation gene sequencing has uncovered genetic etiologies and revolutionized diagnostic practices for many epilepsies. Advances in the field of gene therapy also present the opportunity to address the underlying mechanism of monogenic epilepsies, many of which have only recently been described due to advances in precision medicine and biology. To bring precision medicine and genetic therapies closer to clinical applications, experimental animal models are needed that replicate human disease and reflect the complexities of these disorders. Additionally, identifying and characterizing clinical phenotypes, natural disease course, and meaningful outcome measures from epileptic and neurodevelopmental perspectives are necessary to evaluate therapies in clinical studies. Here, we discuss the range of genetically determined epilepsies, the existing challenges to effective clinical management, and the potential role gene therapy may play in transforming treatment options available for these conditions.<\/jats:p>","DOI":"10.3389\/fneur.2022.805007","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T11:18:47Z","timestamp":1656674327000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Gene Therapy: Novel Approaches to Targeting Monogenic Epilepsies"],"prefix":"10.3389","volume":"13","author":[{"given":"Kimberly","family":"Goodspeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyash","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanchal","family":"Sadhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Holmay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Bilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berge A.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13073-015-0214-7","article-title":"Advancing epilepsy genetics in the genomic era","volume":"7","author":"Myers","year":"2015","journal-title":"Genome Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e152079","DOI":"10.1172\/JCI152079","article-title":"Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model","volume":"131","author":"Li","year":"2021","journal-title":"J Clin Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/humu.23547","article-title":"Partial loss-of-function of sodium channel SCN8A in familial isolated myoclonus","volume":"39","author":"Wagnon","year":"2018","journal-title":"Hum Mutat."},{"key":"B4","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.21366.1","article-title":"Recent advances in epilepsy genomics and genetic testing","volume":"9","author":"Hebbar","year":"2020","journal-title":"F1000Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10048-020-00622-5","article-title":"De novo ARHGEF9 missense variants associated with neurodevelopmental disorder in females: expanding the genotypic and phenotypic spectrum of ARHGEF9 disease in females","volume":"22","author":"Scala","year":"2021","journal-title":"Neurogenetics."},{"key":"B6","doi-asserted-by":"publisher","first-page":"116260","DOI":"10.1016\/j.carbpol.2020.116260","article-title":"Polyglucosan body structure in Lafora disease","volume":"240","author":"Brewer","year":"2020","journal-title":"Carbohyd Polym."},{"key":"B7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ajhg.2014.06.006","article-title":"Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathy with seizure onset in the first days of life","volume":"95","author":"Thevenon","year":"2014","journal-title":"Am J Hum Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.seizure.2011.06.014","article-title":"Variable expressivity of a novel mutation in the SCN1A gene leading to an autosomal dominant seizure disorder","volume":"20","author":"Mhanni","year":"2011","journal-title":"Seizure."},{"key":"B9","doi-asserted-by":"publisher","first-page":"fcaa170","DOI":"10.1093\/braincomms\/fcaa170","article-title":"Current knowledge of SLC6A1-related neurodevelopmental disorders","volume":"2","author":"Goodspeed","year":"2020","journal-title":"Brain Commun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.eplepsyres.2008.10.009","article-title":"A novel mutation of the nicotinic acetylcholine receptor gene CHRNA4 in sporadic nocturnal frontal lobe epilepsy","volume":"83","author":"Chen","year":"2009","journal-title":"Epilepsy Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1073\/pnas.1216867110","article-title":"Genotype\u2013phenotype correlations in neonatal epilepsies caused by mutations in the voltage sensor of Kv7.2 potassium channel subunits","volume":"110","author":"Miceli","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s13311-020-00835-4","article-title":"From genetic testing to precision medicine in epilepsy","volume":"17","author":"Striano","year":"2020","journal-title":"Neurotherapeutics."},{"key":"B13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of intrathecal AAV9 gene therapy for giant axonal neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omtm.2018.10.011","article-title":"Efficacy of a bicistronic vector for correction of Sandhoff disease in a mouse model","volume":"12","author":"Woodley","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/diseases4040033","article-title":"Genetic substrate reduction therapy: a promising approach for lysosomal storage disorders","volume":"4","author":"Coutinho","year":"2016","journal-title":"Diseases."},{"key":"B16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ejhg.2009.144","article-title":"Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease","volume":"18","author":"Dziedzic","year":"2010","journal-title":"Eur J Hum Genet."},{"key":"B17","article-title":"ETX101, a GABAergic interneuron selective AAV-mediated gene therapy for the treatment of SCN1A+ dravet syndrome: biodistribution and safety in non-human primates","volume-title":"Am Epilepsy Soc Abstr.","author":"Belle","year":"2020"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e16402","DOI":"10.1097\/MD.0000000000016402","article-title":"Risk factors for drug-resistant epilepsy: A systematic review and meta-analysis","volume":"98","author":"Xue-Ping","year":"2019","journal-title":"Medicine (Baltimore)."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/epi.14191","article-title":"Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes","volume":"59","author":"de Lange","year":"2018","journal-title":"Epilepsia."},{"key":"B20","first-page":"87","article-title":"Epilepsy: Treatment options","volume":"96","author":"Liu","year":"2017","journal-title":"Am Fam Physician."},{"key":"B21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.nec.2018.12.005","article-title":"Vagus nerve stimulation for the treatment of epilepsy","volume":"30","author":"Gonz\u00e1lez","year":"2019","journal-title":"Neurosurg Clin N Am."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fnins.2019.00005","article-title":"Ketogenic diet and epilepsy: What we know so far","volume":"13","author":"D'Andrea Meira","year":"2019","journal-title":"Front Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2119\/molmed.2016.00077","article-title":"Mutations in the Na(+)\/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay","volume":"22","author":"Klotz","year":"2016","journal-title":"Mol Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5137\/1019-5149.JTN.33775-21.2","article-title":"Vagus nerve stimulation in intractable epilepsy","volume":"32","author":"Boluk","year":"2022","journal-title":"Turk Neurosurg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ane.12737","article-title":"randomized controlled trial of the ketogenic diet in refractory childhood epilepsy","volume":"135","author":"Lambrechts","year":"2017","journal-title":"Acta Neurol Scand."},{"key":"B26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/epi.13381","article-title":"ILAE Genetics Commission. Primer Part 1-The building blocks of epilepsy genetics","volume":"57","author":"Helbig","year":"2016","journal-title":"Epilepsia."},{"key":"B27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood.V91.1.30","article-title":"Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency","volume":"91","author":"Onodera","year":"1998","journal-title":"Blood."},{"key":"B28","unstructured":"U.S. Food & Drug Administration2019"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum Mol Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s11689-018-9234-0","article-title":"Recent progress and considerations for AAV gene therapies targeting the central nervous system","volume":"10","author":"Lykken","year":"2018","journal-title":"J Neurodev Disord."},{"key":"B33","unstructured":"U.S. Food & Drug Administration2021"},{"key":"B34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.seizure.2016.10.014","article-title":"From genotype to phenotype in Dravet disease","volume":"44","author":"Gataullina","year":"2017","journal-title":"Seizure."},{"key":"B35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.expneurol.2018.10.010","article-title":"Gene expression profiling in a mouse model of Dravet syndrome","volume":"311","author":"Hawkins","year":"2019","journal-title":"Exp Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1528-1167.2011.03001.x","article-title":"Dravet syndrome: the long-term outcome","volume":"52","author":"Genton","year":"2011","journal-title":"Epilepsia."},{"key":"B37","first-page":"1","article-title":"scAAV9 gene replacement therapy for epileptic SLC13A5 deficiency","volume":"29","author":"Bailey","year":"2021","journal-title":"Mol Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"39469","DOI":"10.1074\/jbc.M207072200","article-title":"Structure, function, and expression pattern of a novel sodium-coupled citrate transporter (NaCT) cloned from mammalian brain","volume":"277","author":"Inoue","year":"2002","journal-title":"J Biol Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-021-03230-x","article-title":"Structure and inhibition mechanism of the human citrate transporter NaCT","volume":"591","author":"Sauer","year":"2021","journal-title":"Nature."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1111\/epi.16699","article-title":"Neonatal developmental and epileptic encephalopathy due to autosomal recessive variants in SLC13A5 gene","volume":"61","author":"Matricardi","year":"2020","journal-title":"Epilepsia."},{"key":"B41","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cmet.2011.06.009","article-title":"Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice","volume":"14","author":"Birkenfeld","year":"2011","journal-title":"Cell Metab."},{"key":"B42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fncel.2011.00011","article-title":"The role of collybistin in gephyrin clustering at inhibitory synapses: Facts and open questions","volume":"5","author":"Papadopoulos","year":"2011","journal-title":"Front Cell Neurosci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nbd.2018.09.026","article-title":"Wwox deletion leads to reduced GABA-ergic inhibitory interneuron numbers and activation of microglia and astrocytes in mouse hippocampus","volume":"121","author":"Hussain","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8922","DOI":"10.3390\/ijms21238922","article-title":"WWOX loss of function in neurodevelopmental and neurodegenerative disorders","volume":"21","author":"Aldaz","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/hmg\/ddy445","article-title":"The phenotypic landscape of a Tbc1d24 mutant mouse includes convulsive seizures resembling human early infantile epileptic encephalopathy","volume":"28","author":"Tona","year":"2019","journal-title":"Hum Mol Genet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1212\/WNL.0000000000002807","article-title":"TBC1D24 genotype-phenotype correlation: epilepsies and other neurologic features","volume":"87","author":"Balestrini","year":"2016","journal-title":"Neurology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s13311-021-01040-7","article-title":"Targeting gys1 with AAV-SaCas9 decreases pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and Lafora disease mouse models","volume":"18","author":"Gumusgoz","year":"2021","journal-title":"Neurotherapeutics."},{"key":"B48","doi-asserted-by":"publisher","first-page":"7117","DOI":"10.1074\/jbc.R117.803064","article-title":"Lafora disease offers a unique window into neuronal glycogen metabolism","volume":"293","author":"Gentry","year":"2018","journal-title":"J Biol Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1093\/hmg\/ddaa202","article-title":"A novel mouse model for pyridoxine-dependent epilepsy due to antiquitin deficiency","volume":"29","author":"Al-Shekaili","year":"2020","journal-title":"Hum Mol Genet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/dmcn.14385","article-title":"Clinical and genetic features in pyridoxine-dependent epilepsy: a Chinese cohort study","volume":"62","author":"Jiao","year":"2020","journal-title":"Dev Med Child Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/nm.2058","article-title":"Enhanced tonic GABAA inhibition in typical absence epilepsy","volume":"15","author":"Cope","year":"2009","journal-title":"Nat Med."},{"key":"B52","article-title":"Neurodevelopmental phenotypes associated with pathogenic variants in SLC6A1","volume-title":"J Med Genet","author":"Kahen","year":"2021"},{"key":"B53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/2470","article-title":"Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy","volume":"20","author":"Minassian","year":"1998","journal-title":"Nat Genet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ng1238","article-title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy","volume":"35","author":"Chan","year":"2003","journal-title":"Nat Genet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02863929","article-title":"Beitrag zur Histopathologie der myoklonischen Epilepsie: Bearbeitung des klinischen Teiles","volume":"6","author":"Lafora","year":"1911","journal-title":"Zeitschrift f\u00fcr die gesamte Neurologie und Psychiatrie."},{"key":"B56","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41582-018-0057-0","article-title":"Lafora disease - from pathogenesis to treatment strategies","volume":"14","author":"Nitschke","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13023-021-01989-w","article-title":"Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis","volume":"16","author":"Pondrelli","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"103276","DOI":"10.1016\/j.isci.2021.103276","article-title":"An empirical pipeline for personalized diagnosis of Lafora disease mutations","volume":"24","author":"Brewer","year":"2021","journal-title":"iScience."},{"key":"B59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.seizure.2019.08.012","article-title":"The best evidence for progressive myoclonic epilepsy: a pathway to precision therapy","volume":"71","author":"Orsini","year":"2019","journal-title":"Seizure."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/hmg\/11.11.1251","article-title":"Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice","volume":"11","author":"Ganesh","year":"2002","journal-title":"Hum Mol Genet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ana.22156","article-title":"Glycogen hyperphosphorylation underlies lafora body formation","volume":"68","author":"Turnbull","year":"2010","journal-title":"Ann Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ymgme.2017.06.009","article-title":"Analyses of SLC13A5 -epilepsy patients reveal perturbations of TCA cycle","volume":"121","author":"Bainbridge","year":"2017","journal-title":"Mol Genet Metab."},{"key":"B63","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajhg.2019.05.020","article-title":"Ultra-rare genetic variation in the epilepsies: a whole-exome sequencing study of 17,606 individuals","volume":"105","author":"Epi25","year":"2019","journal-title":"Am J Hum Genet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2329048X20931361","DOI":"10.1177\/2329048X20931361","article-title":"Epilepsy and EEG phenotype of SLC13A5 citrate transporter disorder","volume":"7","author":"Yang","year":"2020","journal-title":"Child Neurol Open"},{"key":"B65","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000515434","article-title":"Gene transfer therapy for neurodevelopmental disorders","volume":"43","author":"Ozlu","year":"2021","journal-title":"Dev Neurosci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"105018","DOI":"10.1016\/j.nbd.2020.105018","article-title":"Disruption of the sodium-dependent citrate transporter SLC13A5 in mice causes alterations in brain citrate levels and neuronal network excitability in the hippocampus","volume":"143","author":"Henke","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.ajhg.2015.02.016","article-title":"Mutations in the GABA transporter SLC6A1 cause epilepsy with myoclonic-atonic seizures","volume":"96","author":"Carvill","year":"2015","journal-title":"Am J Hum Genet."},{"key":"B68","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/epi.13986","article-title":"Defining the phenotypic spectrum of SLC6A1 mutations","volume":"59","author":"Johannesen","year":"2018","journal-title":"Epilepsia."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1523\/JNEUROSCI.1143-18.2019","article-title":"Epilepsy gene therapy using an engineered potassium channel","volume":"39","author":"Snowball","year":"2019","journal-title":"J Neurosci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1523\/JNEUROSCI.4056-03.2004","article-title":"Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus","volume":"24","author":"Richichi","year":"2004","journal-title":"J Neurosci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"690404","DOI":"10.3389\/fneur.2021.690404","article-title":"Seizure diaries and forecasting with wearables: epilepsy monitoring outside the clinic","volume":"12","author":"Brinkmann","year":"2021","journal-title":"Front Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1684\/epd.2015.0739","article-title":"Cognitive impairment in epilepsy: the role of network abnormalities","volume":"17","author":"Holmes","year":"2015","journal-title":"Epileptic Disord."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag."},{"key":"B74","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ebcr.2014.09.003","article-title":"Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel","volume":"2","author":"Dirani","year":"2014","journal-title":"Epilepsy Behav Case Rep."},{"key":"B75","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/epi4.12281","article-title":"Autism spectrum disorder and cognitive profile in children with Dravet syndrome: Delineation of a specific phenotype","volume":"4","author":"Ouss","year":"2019","journal-title":"Epilepsia Open."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.805007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T11:18:58Z","timestamp":1656674338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.805007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":75,"alternative-id":["10.3389\/fneur.2022.805007"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.805007","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"article-number":"805007"}}